Leukemia Research
Volume 29, Issue 6 , Pages 605-606 , June 2005

The rationale engineering of BCR/ABL blockers: an answer to STI571 acquired resistance in leukemia treatment

Received 24 November 2004

References 

  1. Nowell P, Hungerford D. A minute chromosome in human chromic granulocytic leukemia. Science. 1960;132:1497
  2. Kolibaba KS, Druker BJ. Protein tyrosine kinases and cancer. Biochim Biophys Acta. 1997;1333:217–248
  3. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinse activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079–1082
  4. Raitano AB, Whang YE, Sawyers CL. Signal transduction by wild-type and leukemogenic Abl proteins. Biochim Biophys Acta. 1997;1333:201–216
  5. Zou X, Calame K. Signaling pathways activated by oncogenic forms of Abl tyrosine kinase. J Biol Chem. 1999;274:18141–18144
  6. Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, et al. Fusion tyrosine kinases induce therapeutic drug resistance by stimulation of homology-dependent recombination repair, prolongation of G2/M phase and protection from apoptosis. Mol Cell Biol. 2002;22:4189–4201
  7. Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO, et al. BCR/ABL regulates mammalian RecA homologs resulting in drug resistance. Mol Cell. 2001;8:795–806
  8. Majsterek I, Blasiak J, Mlynarski W, Hoser G, Skorski T. Does the bcr/abl-mediated increase in the efficacy of DNA repair play a role in the drug resistance of cancer cells?. Cell Biol Int. 2002;26:363–370
  9. Hoser G, Majsterek I, Romana DL, Slupianek A, Blasiak J, Skorski T. Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?. Leuk Res. 2003;27:267–273
  10. Majsterek I, Slupianek A, Blasiak J. TEL-fusion oncogenic tyrosine kinases determine leukemic cells response to idarubicin. Anticancer Drugs. 2003;14:625–631
  11. Majsterek I, Slupianek A, Hoser G, Skorski T, Blasiak J. ABL-fusion oncoproteins activate multi-pathway of DNA repair: role in drug resistance?. Biochimie. 2004;86:53–65
  12. Druker BJ. Chronic myeloid leukemia in the imatinib era. Semin Hematol. 2003;40:50–58
  13. Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev. 2003;55:401–423
  14. Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004;18:1321–1331
  15. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 2003;112:831–843
  16. Gambacorti-Passerini C, Piazza R, D’Incalci M. Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels. Blood. 2003;102:1933–1934
  17. Yoshida C, Melo JV. Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int J Hematol. 2004;79:420–433
  18. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, et al. In vitro cytotoxic effects of a trosine inhibitor STI571 in combination with commonly used antileukemic agents. Blood. 2001;97:1999–2007
  19. Qiyu Q, Dudouit F, Matheson SL, Brahini F, Banerjee R, McNamee JP, et al. The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properities. Cancer Chemother Pharmacol. 2003;51:1–10
  20. Matheson S, McNamee J, Jean-Claude BJ. Design of a chimeric 3-methyl-1,2,3,-triazene with mixed recptor tyrosine kinase and DNA damaging properities: a novel tumour targeting strategy. J Pharmacol Exp Ther. 2001;296:832–840
  21. Newlands ES, Stevens MFG , Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properities, pre-clinical dvelopment and clinical trials. Cancer Treat Rev. 1997;23:35–61
  22. Thiesing JT, Ohno-Jones J, Kolibaba KS, Drucker BJ. Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileucemic agents against Bcr-Abl-positive cells. Blood. 2000;96:3195–3199
  23. Katsoulas A, Rachid Z, Brahimi F, McNamee J, Jean-Claude BJ. Engineering 3-alkyltriazenes to block BCR-ABL kinase: a novel strategy for the therapy of advanced BCR-ABL expressing leukemias. Leuk Res. 2005;

PII: S0145-2126(05)00026-3

doi: 10.1016/j.leukres.2004.11.019

Leukemia Research
Volume 29, Issue 6 , Pages 605-606 , June 2005

Article Tools